Concerns about the off-licence use of amiodarone for Ebola

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Gupta Wright, Ankur ^a   Lavers, James ^b   Irvine, Sharon ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b YSBYTY GWYNEDD   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DIURETIC AGENT;

ACUTE KIDNEY FAILURE; CLINICAL PRACTICE; COMPASSIONATE USE; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEART DISEASE; HUMAN; INFORMED CONSENT; LETTER; LIVER DISEASE; LUNG DISEASE; MEDICAL ETHICS; UNLICENSED DRUG USE; WORLD HEALTH ORGANIZATION; DRUG EFFECTS; EBOLA VIRUS; HEMORRHAGIC FEVER, EBOLA; VIRUS ENTRY;

AMIODARONE; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; VIRUS INTERNALIZATION;

EID: 84921761773     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h272     Document Type: Letter

References (4)

1. Turone F. Doctors trial amiodarone for Ebola in Sierra Leone. BMJ 2014;349:g7198. (27 November.)
2. Chen C-C, Wu C-C. Acute hepatotoxicity of intravenous amiodarone: case report and review of the literature. Am J Ther 2014 Sep 24. [Epub ahead of print].
3. Range FT, Hilker E, Breithardt G, Buerke B, Lebiedz P. Amiodarone-induced pulmonary toxicity - a fatal case report and literature review. Cardiovasc Drugs Ther 2013;27:247-54.
4. WHO. Potential Ebola therapies and vaccines. 2014. www.who.int/csr/resources/publications/ebola/potential-therapies-vaccines/en/.